Skip to main content
ANAB
NASDAQ Life Sciences

Officer Dennis Mulroy Files to Sell Additional $1.03M in Stock, Continuing Recent Trend

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$51.33
Mkt Cap
$1.494B
52W Low
$11.402
52W High
$72.36
52W Position info
350% above low
Off High info
29% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $11.402 on light trading volume (0.2× avg).

Summary

Officer Dennis Mulroy has filed to sell an additional $1.03 million in company stock, extending a recent pattern of significant insider selling that totals over $8.8 million in the last three months.


Key Events · Ownership and Investor Activity · ANAB

  • Officer Files Intent to Sell

    Officer Dennis Mulroy has filed a Form 144 indicating intent to sell 20,000 shares of common stock, with an approximate market value of $1,035,438.00.

  • Continuation of Selling Pattern

    This filing is the latest in a series of sales by Dennis Mulroy, who has sold a cumulative total of 138,422 shares, generating gross proceeds of $7,797,889.52, in the past three months, in addition to this proposed sale.

  • Option Exercise and Sale

    The shares to be sold were acquired through a stock option exercise on the same day as the proposed sale date, indicating a liquidity event rather than a direct open-market sale of previously held shares.

  • Conflicting Capital Allocation Signals

    The ongoing insider selling by an officer contrasts with the company's recent announcement of a $100 million share repurchase program, creating mixed signals regarding capital allocation and insider confidence.


Analysis · ANAB · Life Sciences

Officer Dennis Mulroy has filed to sell an additional $1.03 million worth of common stock. This transaction is part of a sustained pattern of insider selling by Mulroy, who has sold over $8.8 million in shares over the past three months. This ongoing distribution by a key officer, often involving the exercise of stock options followed by immediate sale, presents a negative signal, especially as it occurs after the company announced a $100 million share repurchase program.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANAB was trading at $51.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Nov 18, 2026, 7:03 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $47.74
Real-time Price: $46.63 info
Change: -$1.11 (-2%) info
Market Cap: $1.386B info
ANAB
Nov 18, 2026, 6:56 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $47.06
Real-time Price: $46.63 info
Change: -$0.430 (-0.91%) info
Market Cap: $1.386B info
ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $46.63 info
Change: -$1.14 (-2%) info
Market Cap: $1.386B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $46.63 info
Change: -$1.14 (-2%) info
Market Cap: $1.386B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $46.63 info
Change: +$1.63 (+4%) info
Market Cap: $1.386B info